MalariaOMDANCT01976325
Evaluating the Ottawa Malaria Decision Aid
A study testing Ottawa Malaria Decision Aid in people with Malaria, run by Ottawa Hospital Research Institute at 3 sites in Canada.
Trial summary
BRIEF SUMMARY Canadians often visit areas with malaria where the preventative drug chloroquine no longer works. This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Malaria
- What is being tested?
- Ottawa Malaria Decision Aid
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 3 sitesCanada
- Study dates
- Jan 2014to Nov 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- An Adult 18 years of age or older
- Individuals who have contacted the travel clinic at The Ottawa Hospital, General Campus, the National Capital Region Occupational Health Clinic or received study information from IAMAT before they travel
- Travelling for less than one year
- Departing for the trip in more than one week
- Travelling to an area with known chloroquine-resistant malaria
Who cannot join
- The travellers not visiting areas with chloroquine resistant malaria
- Those travelling longer than one year
- Departing for the trip in less than one week
- Individuals younger than 18 years of age
- Those who are pregnant or intend to become pregnant during their travel
- Those who have severe kidney disease, severe liver disease, heart rhythm problems, or a history of seizures
Show all 9Show fewer
- Those who have a history of mental problems
- Those who have an allergy to Atovaquone-proguanil, Doxycycline or Mefloquine
- Those who are unable to understand written or spoken English or French due to deafness, blindness, cognitive impairment or language barrier
Trial locations and contacts
3 sites in 1 country.
Canada3 sites, 3 recruiting
- Recruiting
National Capital Region Occupational Health Clinic
Ottawa, Ontario, K1A 0K9
Louise J Levesque, RN, BScN, 613-946-5533, louise.j.levesque@hc-sc.gc.ca
Lisa Taras, MD, CCFP, 613-946-6583, lisa.taras@hc-sc.gc.ca
- Recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, K1Y 4E9
Charde A Morgan, MScPH, 613-737-8899 ext. 72424, cmorgan@ohri.ca
Anne E McCarthy, MD, 613-737-8899 ext. 78184, amccarthy@toh.on.ca
- Recruiting
International Association for Medical Assistance to Travellers
Toronto, Ontario, M6K 3E3
Tullia Marcolongo, 416-652-0137, tullia@iamat.org
About this study
Official title: Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care
BRIEF SUMMARY
Canadians often visit areas with malaria where the preventative drug chloroquine no longer works.
Read more
This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. There are more than 400 cases of malaria reported in Canada each year, a few which result in death. These cases mainly occur in people who do not take malaria pills as directed.
Investigators have developed the Ottawa Malaria Decision Aid (OMDA), which is a bilingual (English and French) resource used to support malaria prevention decision-making. The OMDA contains plain language, fact-based information and helps individuals to reflect on their own values and beliefs so that they can make the best decision for their situation.
In this randomized control study, the investigators will attempt to find out if using the OMDA before visiting a travel clinic affects decisional conflict and the way pills are taken. Consenting travellers will be assigned to standard care or standard care plus the malaria decision aid. Both groups will complete three questionnaires before and after travel to look at the impact on decisional conflict, preparation for decision-making, decisional regret and pill taking behaviour.
Travelers' malaria can be prevented. It is our hope that by using different methods of presenting information, specifically by utilizing the OMDA, there will be an increase in adherence to appropriate malaria prophylaxis which will ultimately result in a decrease in malaria cases that arrive in Canada. This will translate into a decreased use of health care dollars and unnecessary deaths.
The Objectives of this study are to evaluate whether the malaria decision aid can be integrated into the pre-travel consultation process and can:
- improve a traveller's knowledge of malaria and prevention strategies;
- improve a traveller's preparation for decision-making;
- decrease decisional conflict; and
- affect levels of adherence to prescribed malaria chemoprophylaxis.
The hypotheses of this study are that:
- A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills.
- Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis.
Read the detailed description
RECRUITMENT
The participants will be recruited from the travel medicine clinic at The Ottawa Hospital General Campus, the National Capital Region Occupational Health Clinic, and through The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. The study will undergo a recruitment process that is estimated to last for approximately one year, or until at least 100 patients complete all three questionnaires.
Recruitment begins at the time of initial contact with the travel clinic or IAMAT. Travelers routinely phone, email or fax the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information.
Recruitment at The Ottawa Hospital - General Campus Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely phone the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information. At the time of booking, the clerk fills out a "Traveller Information Form", which contains an individual's name and contact information, lists the dates they will travel, and the countries that they plan to travel to. All travelers will be asked by the clerk if they would agree to be contacted by a researcher for a study. If they say yes, and the countries listed on the form are in line with those chosen for recruiting participants, the research assistant will contact them by the email or telephone number listed. The research assistant will send/read an email/telephone script which introduces the study and will ask participants if they would be interested in learning more. If they say yes, they will be provided with the study website information (a small paragraph describing the study with a link to study registration). Because the investigators recognize the difficulty of writing down website addresses, the traveller will have the option to provide the research assistant with their email address, if the research assistant does not have it already, and have the study website address sent to them electronically by the research assistant. The research assistant will not retain any personal information for any clients contacted at any time in the recruitment stage. The only information collected during recruitment will be the net number of clients called/emailed, and the net number who indicated that they would be interested in participating.
Recruitment at the National Capital Region Clinic Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely email the travel clinic. Then they are sent a form to complete and email or fax. For all travellers planning to visit an area with chloroquine-resistant malaria for one year or less, the clerk will send an email attachment of the study recruitment information, including the study website information. No personal information about the individuals contacted will be collected by the study team. The clerk only will relay the net number of individuals contacted to the study research assistant.
Recruitment through travel health advertising: eNewsletters and social media Recruitment will begin through social media and email newsletters to subscribing members. Travel medicine associations with members who subscribe to receive travel health information will post the recruitment script in eNewsletters and on social media websites as part of their normal advertising procedures. When travellers observe the recruitment script in the newsletter or on a social media website, they can click on the link located within it, which will bring them to the study website. If they pass the eligibility criteria, individuals are invited to proceed to complete the recruitment process as described below.
An example of one organization which will post the recruitment message is The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. IAMAT specializes in providing pre-trip travel health advice and coordinates an international network of physicians and travel clinics. IAMAT would add the currently approved recruitment text to their eNewsletter, and put the text on their social media websites. Only subscribing members to their email listserv or visitors to their social media accounts will receive the information about the study.
----------
STUDY PROGRESSION
All potential study participants will be sent a link by email to the study website. In the case of IAMAT, subscribing members will receive information about the study containing the study link. Upon clicking on the link, they will be directed to the traveler information and consent form page. The page contains information about why the research is being conducted, the purpose of the study, a description of the study, outlines the risks and benefits of participation, and asks participants for voluntary consent to participate.
If interested in participating, then they will be asked to acknowledge that they have reviewed the traveler information and consent form page. Those agreeing to participate will be directed to an eligibility page. They will be asked questions to ensure that they are eligible for study participation. If they are eligible, they will be invited to participate and register their email address for the study. They will be informed that by logging on to the website, they will be providing their implied consent for participation in the study.
Once a participant enters their registration information, they will be sent a link to their email address that they must click on in order to begin the first survey.
All groups will complete all three surveys at the times described below. The randomization process will take place during the Baseline survey.
- The Baseline survey is to be done before the pre-travel clinic consultation;
- The Post-Consult survey is to be completed immediately after the travel medicine consultation; and
- The Post-chemoprophylaxis questionnaire is to be completed one week after the expected date of finishing chemoprophylaxis.
Once a participant completes all three surveys, in return for their time and dedication to the study, participants who reside in Canada will be offered a $5 gift card to a popular Canadian coffee chain (Tim Horton's).
----------
RANDOMIZATION PROCESS
Upon beginning the Baseline questionnaire, all participants will be randomized centrally into two groups.
- Group 1 will receive standard pre-travel information through the pre-travel consultation process.
- Group 2 will receive The Ottawa Malaria Decision Aid plus standard pre-travel information through the pre-travel consultation process.
For those randomized to Group 2, the decision aid has been embedded in the baseline survey. The Decision Aid provides comparative information about malaria pill options; communicates probabilities for the risk of malaria; and clarifies values.
All other questionnaires and standard medical care will remain the same for both groups of participants.
----------
CONFIDENTIALITY
All data collected will be coded with an independent study number and kept anonymous. The file linking codes to patient names will be stored in a locked filling cabinet at The Ottawa Hospital and stored separately from the main project files in one of Dr. McCarthy's offices. Only the research team will have access to these files.
Electronic files will contain anonymized information and will be password protected and stored in the secure TOH servers behind the The Ottawa Hospital firewall. These data will only contain assigned study numbers to identify data sets. Only the research team will have access to this information.
Study records may be audited by the Ottawa Hospital Research Ethics Board (OHREB).
Participants will not be able to be identified in any of the publications resulting from this project.
----------
PATIENT RISK
There are no risks anticipated in this study. Participation in the study is voluntary and will not affect the participant's routine medical care. Patients expressing concerns about the information in the decision aid will be referred to their individual physician or travel clinic physician or nurse.
- Conditions
- Malaria
- Being tested
- Ottawa Malaria Decision Aid
- Keywords
- decision aid, imported malaria, malaria prevention and control, malaria chemoprophylaxis, mefloquine, lariam, atovaquone-proguanil, malarone, doxycycline, vibramycin
- Medical subject headings
- Malaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ottawa Malaria Decision AidOther
The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
| Study group | Role | What they receive |
|---|---|---|
| Standard Care | No intervention | This arm will receive no intervention; only standard medical care. |
| Decision Aid + Standard Care | Experimental | This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care. Receives: Other: Ottawa Malaria Decision Aid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Travellers' Knowledge Score
The traveller's knowledge score will be calculated based on participant's answers to questions from the Ottawa Malaria Knowledge Scale (2007) and the Realistic Expectations Scale (O'Connor 1996). For each multiple choice question, every possible response contains a predetermined scoring scheme. The traveller's knowledge score is calculated by adding points from each question answered. The sum of points forms the traveller's knowledge score.
Measured: One year
Secondary outcomes (3)
Decisional Conflict Score
The decisional conflict score will be measured based on responses in the questionnaire using specific questions from the Decisional Conflict Scale (O'Connor, 1993, revised 2005), the Medical Decision Making Scale (Adapted from Strull, 1984), the Values Scale (Adapted from O'Connor 1999), and the Decision Regret Scale (O'Connor, 1996). For each scaled question, every possible response contains a predetermined scoring scheme. The score is calculated by adding points from each question answered. The sum of points forms the score.
Measured: One year
Preparation for Decision-making Score
The preparation for decision making score will be measured based on responses in the questionnaire using specific questions from the Preparation for Decision Making Scale (Graham, O'Connor 1996, revised 2005), and the Choice Predisposition Scale (O'Connor 2000). For each scaled question, every possible response contains a predetermined scoring scheme. The score is calculated by adding points from each question answered. The sum of points forms the score.
Measured: One year
Medication Adherence Score
Medication adherence will be measured based on responses in the after-travel questionnaire using specific questions from the adapted ACTG Adherence questionnaire, and the Malaria Adherence Prophylactic Scale (MAPS). For each multiple choice and scaled question, every possible response contains a predetermined scoring scheme. The score is calculated by adding points from each question answered. The sum of points forms the score.
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2013 (estimated)
- Study startJan 2014
- Primary completionNov 2015 (estimated)
- Study completionNov 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for MalariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ottawa Hospital Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anne E McCarthy, MD, MSc, Principal investigator, Ottawa Hospital Research InstituteCatherine Ivory, PhD, Study chair, University of Ottawa, Faculty of MedicineLouise Balfour, PhD, Study chair, Ottawa Hospital Research InstituteCharde A Morgan, MScPH, Study chair, Ottawa Hospital Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01976325
- Sponsor's protocol ID
- 2010462-01H
- Acronym
- OMDA
- Status last verified
- Apr 2015
- First submitted
- 29 Oct 2013
- Last updated
- 16 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian recommendations for the prevention and treatment of malaria among international travellers--2009. Can Commun Dis Rep. 2009 Jul;35 Suppl 1:1-82. No abstract available.
PubMed 19750611Steffen R, deBernardis C, Banos A. Travel epidemiology--a global perspective. Int J Antimicrob Agents. 2003 Feb;21(2):89-95. doi: 10.1016/s0924-8579(02)00293-5.
PubMed 12615369Conner BA. Expert recommendations for antimalarial prophylaxis. J Travel Med. 2001 Dec;8(Suppl 3):S57-64. No abstract available.
PubMed 12186677Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998 Mar 7;351(9104):709-13. doi: 10.1016/S0140-6736(97)09222-2.
PubMed 9504515Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001 Oct 1;33(7):1015-21. doi: 10.1086/322694. Epub 2001 Sep 5.
PubMed 11528574Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003 Nov 8;327(7423):1078. doi: 10.1136/bmj.327.7423.1078.
PubMed 14604928Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg. 1999 Apr;60(4):521-5. doi: 10.4269/ajtmh.1999.60.521.
PubMed 10348223Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, Scott TR. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis. 1998 Sep;27(3):494-9. doi: 10.1086/514710.
PubMed 9770146Sossouhounto RT, Soro BN, Coulibaly A, Mittelholzer ML, Stuerchler D, Haller L. Mefloquine in the Prophylaxis of P. Falciparum Malaria. J Travel Med. 1995 Dec 1;2(4):221-224. doi: 10.1111/j.1708-8305.1995.tb00663.x.
PubMed 9815395Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003 Mar 1;36(5):541-9. doi: 10.1086/367542. Epub 2003 Feb 14.
PubMed 12594633Suh KN, Kain KC, Keystone JS. Malaria. CMAJ. 2004 May 25;170(11):1693-702. doi: 10.1503/cmaj.1030418.
PubMed 15159369Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med. 2006 Jan-Feb;13(1):8-14. doi: 10.1111/j.1708-8305.2006.00005.x.
PubMed 16412104Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health. 2005 Nov;10(4):355-72. doi: 10.1080/13557850500242035.
PubMed 16191732O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001431. doi: 10.1002/14651858.CD001431.pub2.
PubMed 19588325Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A, Ruland C, Sepucha K, Sykes A, Whelan T; International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006 Aug 26;333(7565):417. doi: 10.1136/bmj.38926.629329.AE. Epub 2006 Aug 14.
PubMed 16908462
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care
- ClinicalTrials.gov ID
- NCT01976325
- Acronym / sponsor ID
- OMDA / 2010462-01H
- Conditions
- Malaria
- Keywords
- decision aid, imported malaria, malaria prevention and control, malaria chemoprophylaxis, mefloquine, lariam, atovaquone-proguanil, malarone
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Ottawa Hospital Research InstituteUniversity, hospital or other
- Study start
- Jan 2014
- Primary completion
- Nov 2015 (estimated)
- Study completion
- Nov 2015 (estimated)
- First posted
- 5 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BRIEF SUMMARY
Canadians often visit areas with malaria where the preventative drug chloroquine no longer works.
This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. There are more than 400 cases of malaria reported in Canada each year, a few which result in death. These cases mainly occur in people who do not take malaria pills as directed.
Investigators have developed the Ottawa Malaria Decision Aid (OMDA), which is a bilingual (English and French) resource used to support malaria prevention decision-making. The OMDA contains plain language, fact-based information and helps individuals to reflect on their own values and beliefs so that they can make the best decision for their situation.
In this randomized control study, the investigators will attempt to find out if using the OMDA before visiting a travel clinic affects decisional conflict and the way pills are taken. Consenting travellers will be assigned to standard care or standard care plus the malaria decision aid. Both groups will complete three questionnaires before and after travel to look at the impact on decisional conflict, preparation for decision-making, decisional regret and pill taking behaviour.
Travelers' malaria can be prevented. It is our hope that by using different methods of presenting information, specifically by utilizing the OMDA, there will be an increase in adherence to appropriate malaria prophylaxis which will ultimately result in a decrease in malaria cases that arrive in Canada. This will translate into a decreased use of health care dollars and unnecessary deaths.
The Objectives of this study are to evaluate whether the malaria decision aid can be integrated into the pre-travel consultation process and can:
- improve a traveller's knowledge of malaria and prevention strategies;
- improve a traveller's preparation for decision-making;
- decrease decisional conflict; and
- affect levels of adherence to prescribed malaria chemoprophylaxis.
The hypotheses of this study are that:
- A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills.
- Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis.
Detailed description
RECRUITMENT
The participants will be recruited from the travel medicine clinic at The Ottawa Hospital General Campus, the National Capital Region Occupational Health Clinic, and through The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. The study will undergo a recruitment process that is estimated to last for approximately one year, or until at least 100 patients complete all three questionnaires.
Recruitment begins at the time of initial contact with the travel clinic or IAMAT. Travelers routinely phone, email or fax the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information.
Recruitment at The Ottawa Hospital - General Campus Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely phone the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information. At the time of booking, the clerk fills out a "Traveller Information Form", which contains an individual's name and contact information, lists the dates they will travel, and the countries that they plan to travel to. All travelers will be asked by the clerk if they would agree to be contacted by a researcher for a study. If they say yes, and the countries listed on the form are in line with those chosen for recruiting participants, the research assistant will contact them by the email or telephone number listed. The research assistant will send/read an email/telephone script which introduces the study and will ask participants if they would be interested in learning more. If they say yes, they will be provided with the study website information (a small paragraph describing the study with a link to study registration). Because the investigators recognize the difficulty of writing down website addresses, the traveller will have the option to provide the research assistant with their email address, if the research assistant does not have it already, and have the study website address sent to them electronically by the research assistant. The research assistant will not retain any personal information for any clients contacted at any time in the recruitment stage. The only information collected during recruitment will be the net number of clients called/emailed, and the net number who indicated that they would be interested in participating.
Recruitment at the National Capital Region Clinic Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely email the travel clinic. Then they are sent a form to complete and email or fax. For all travellers planning to visit an area with chloroquine-resistant malaria for one year or less, the clerk will send an email attachment of the study recruitment information, including the study website information. No personal information about the individuals contacted will be collected by the study team. The clerk only will relay the net number of individuals contacted to the study research assistant.
Recruitment through travel health advertising: eNewsletters and social media Recruitment will begin through social media and email newsletters to subscribing members. Travel medicine associations with members who subscribe to receive travel health information will post the recruitment script in eNewsletters and on social media websites as part of their normal advertising procedures. When travellers observe the recruitment script in the newsletter or on a social media website, they can click on the link located within it, which will bring them to the study website. If they pass the eligibility criteria, individuals are invited to proceed to complete the recruitment process as described below.
An example of one organization which will post the recruitment message is The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. IAMAT specializes in providing pre-trip travel health advice and coordinates an international network of physicians and travel clinics. IAMAT would add the currently approved recruitment text to their eNewsletter, and put the text on their social media websites. Only subscribing members to their email listserv or visitors to their social media accounts will receive the information about the study.
----------
STUDY PROGRESSION
All potential study participants will be sent a link by email to the study website. In the case of IAMAT, subscribing members will receive information about the study containing the study link. Upon clicking on the link, they will be directed to the traveler information and consent form page. The page contains information about why the research is being conducted, the purpose of the study, a description of the study, outlines the risks and benefits of participation, and asks participants for voluntary consent to participate.
If interested in participating, then they will be asked to acknowledge that they have reviewed the traveler information and consent form page. Those agreeing to participate will be directed to an eligibility page. They will be asked questions to ensure that they are eligible for study participation. If they are eligible, they will be invited to participate and register their email address for the study. They will be informed that by logging on to the website, they will be providing their implied consent for participation in the study.
Once a participant enters their registration information, they will be sent a link to their email address that they must click on in order to begin the first survey.
All groups will complete all three surveys at the times described below. The randomization process will take place during the Baseline survey.
- The Baseline survey is to be done before the pre-travel clinic consultation;
- The Post-Consult survey is to be completed immediately after the travel medicine consultation; and
- The Post-chemoprophylaxis questionnaire is to be completed one week after the expected date of finishing chemoprophylaxis.
Once a participant completes all three surveys, in return for their time and dedication to the study, participants who reside in Canada will be offered a $5 gift card to a popular Canadian coffee chain (Tim Horton's).
----------
RANDOMIZATION PROCESS
Upon beginning the Baseline questionnaire, all participants will be randomized centrally into two groups.
- Group 1 will receive standard pre-travel information through the pre-travel consultation process.
- Group 2 will receive The Ottawa Malaria Decision Aid plus standard pre-travel information through the pre-travel consultation process.
For those randomized to Group 2, the decision aid has been embedded in the baseline survey. The Decision Aid provides comparative information about malaria pill options; communicates probabilities for the risk of malaria; and clarifies values.
All other questionnaires and standard medical care will remain the same for both groups of participants.
----------
CONFIDENTIALITY
All data collected will be coded with an independent study number and kept anonymous. The file linking codes to patient names will be stored in a locked filling cabinet at The Ottawa Hospital and stored separately from the main project files in one of Dr. McCarthy's offices. Only the research team will have access to these files.
Electronic files will contain anonymized information and will be password protected and stored in the secure TOH servers behind the The Ottawa Hospital firewall. These data will only contain assigned study numbers to identify data sets. Only the research team will have access to this information.
Study records may be audited by the Ottawa Hospital Research Ethics Board (OHREB).
Participants will not be able to be identified in any of the publications resulting from this project.
----------
PATIENT RISK
There are no risks anticipated in this study. Participation in the study is voluntary and will not affect the participant's routine medical care. Patients expressing concerns about the information in the decision aid will be referred to their individual physician or travel clinic physician or nurse.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Care | No intervention | –This arm will receive no intervention; only standard medical care. |
| Decision Aid + Standard Care | Experimental | Other: Ottawa Malaria Decision AidThis group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- An Adult 18 years of age or older
- Individuals who have contacted the travel clinic at The Ottawa Hospital, General Campus, the National Capital Region Occupational Health Clinic or received study information from IAMAT before they travel
- Travelling for less than one year
- Departing for the trip in more than one week
- Travelling to an area with known chloroquine-resistant malaria
Key exclusion criteria (9 listed)
- The travellers not visiting areas with chloroquine resistant malaria
- Those travelling longer than one year
- Departing for the trip in less than one week
- Individuals younger than 18 years of age
- Those who are pregnant or intend to become pregnant during their travel
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ottawa Malaria Decision AidThe Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner. | Other | Decision Aid + Standard Care |
Primary outcome
Travellers' Knowledge Score
Time frame: One year
The traveller's knowledge score will be calculated based on participant's answers to questions from the Ottawa Malaria Knowledge Scale (2007) and the Realistic Expectations Scale (O'Connor 1996). For each multiple choice question, every possible response contains a predetermined scoring scheme. The traveller's knowledge score is calculated by adding points from each question answered. The sum of points forms the traveller's knowledge score.
3 secondary outcomes
Decisional Conflict Score
Time frame: One year
Preparation for Decision-making Score
Time frame: One year
Medication Adherence Score
Time frame: One year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2015.
- Background: PubMed 19750611Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian recommendations for the prevention and treatment of malaria among international travellers--2009. Can Commun Dis Rep. 2009 Jul;35 Suppl 1:1-82. No abstract available.
- Background: PubMed 12615369Steffen R, deBernardis C, Banos A. Travel epidemiology--a global perspective. Int J Antimicrob Agents. 2003 Feb;21(2):89-95. doi: 10.1016/s0924-8579(02)00293-5.
- Background: PubMed 12186677Conner BA. Expert recommendations for antimalarial prophylaxis. J Travel Med. 2001 Dec;8(Suppl 3):S57-64. No abstract available.
- Background: PubMed 9504515Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998 Mar 7;351(9104):709-13. doi: 10.1016/S0140-6736(97)09222-2.
- Background: PubMed 11528574Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001 Oct 1;33(7):1015-21. doi: 10.1086/322694. Epub 2001 Sep 5.
- Background: PubMed 14604928Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003 Nov 8;327(7423):1078. doi: 10.1136/bmj.327.7423.1078.
- Background: PubMed 10348223Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg. 1999 Apr;60(4):521-5. doi: 10.4269/ajtmh.1999.60.521.
- Background: PubMed 9770146Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, Scott TR. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis. 1998 Sep;27(3):494-9. doi: 10.1086/514710.
- Background: PubMed 9815395Sossouhounto RT, Soro BN, Coulibaly A, Mittelholzer ML, Stuerchler D, Haller L. Mefloquine in the Prophylaxis of P. Falciparum Malaria. J Travel Med. 1995 Dec 1;2(4):221-224. doi: 10.1111/j.1708-8305.1995.tb00663.x.
- Background: PubMed 12594633Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003 Mar 1;36(5):541-9. doi: 10.1086/367542. Epub 2003 Feb 14.
- Background: PubMed 15159369Suh KN, Kain KC, Keystone JS. Malaria. CMAJ. 2004 May 25;170(11):1693-702. doi: 10.1503/cmaj.1030418.
- Background: PubMed 16412104Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med. 2006 Jan-Feb;13(1):8-14. doi: 10.1111/j.1708-8305.2006.00005.x.
- The Ottawa HospitalLink provided by the sponsor.
- The Ottawa Hospital Research InstituteLink provided by the sponsor.
- Patient Decision Aids at The Ottawa Hospital Research InstituteLink provided by the sponsor.
- Canadian Centre for Occupational Health and SafetyLink provided by the sponsor.
- Travel Health at the Public Health Agency of CanadaLink provided by the sponsor.
- International Association for Medical Assistance to TravellersLink provided by the sponsor.
Related trials for Malaria
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Not yet recruitingObservational study
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
Malaria
RecruitingPhase 1
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Malaria
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1/2
DON in Pediatric Cerebral Malaria
Malaria, Cerebral
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anne E McCarthy, MD, MSc principal investigator
Ottawa Hospital Research Institute
Catherine Ivory, PhD study chair
University of Ottawa, Faculty of Medicine
Louise Balfour, PhD study chair
Ottawa Hospital Research Institute
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ottawa Malaria Decision Aid in people with Malaria, run by Ottawa Hospital Research Institute at 3 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Charde A Morgan, MScPH (613-737-8899 ext. 72424, cmorgan@ohri.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Travellers' Knowledge Score (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01976325, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2015.